

Ryan Sansom

Partner



rsansom@cooley.com

+1 617 937 2335

Boston

Emerging Companies

Life Sciences

Life Sciences Corporate Partnering and Licensing

Cleantech

Public Companies

Capital Markets

Venture Capital

Ryan Sansom centers his practice on advising privately held and publicly traded emerging companies, with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, healthcare IT and health and wellness. Ryan's representation of life sciences and technology companies spans the entire emerging company life-cycle, including pre-incorporation planning, formation and founder matters, seed, venture capital and growth equity financings, public offerings and mergers and acquisitions, and other complex transactions. In addition, Ryan often represents venture capital firms in connection with their investments in emerging companies and underwriters in connection with public offerings by emerging companies.

Ryan is also a member of the AMC White Mountain Club having summited all 48 NH 4000 Foot Peaks.

Representative Experience

Public Offerings

- Milestone Pharmaceuticals in its \$94.9 million initial public offering
- Ra Pharmaceuticals in its \$105.4 million initial public offering* and subsequently represented the underwriters in the \$149.5 million and \$130 million follow-on public offerings of Ra Pharmaceuticals
- Underwriters in the \$60.7 million initial public offering of Bicycle Therapeutics
- ObsEva in its \$73.1 million follow-on public offering
- Jounce Therapeutics in its \$104 million initial public offering*
- Dimension Therapeutics in its \$72 million initial public offering*
- Underwriters in the \$65 million initial public offering, \$85 million follow-on financing, \$77 million follow-on financing and \$74.5 million follow-on financing of Flexion Therapeutics*
- Imprivata in its \$75 million initial public offering and \$68.5 million follow-on public offering*
- Underwriters in the \$73 million initial public offering of Aquestive Therapeutics
- Minerva in its \$41.88 million follow-on public offering
- Vericel (f/k/a Aastrom Bioscience) in its \$35 million follow-on public offering*
- BofA Merrill Lynch and Leerink Partners in the \$60 million initial public offering of Roka Bioscience*

Private Financings

- Milestone Pharmaceuticals in its \$80 million private financing
- Turnstone Biologics in its \$42 million Series C financing
- Therachon in its \$60 million Series B financing
- 5AM Ventures in their investment in the \$37 million Series A financing of Rallybio
- New Enterprise Associates in their \$50.5 million Series C investment in Trevi Therapeutics
- 5AM Ventures in their investment in the \$38 million Series A financing of Cabaletta Bio
- Wellington Management Company in Braeburn Pharmaceuticals' \$100 million financing
- Formlabs' \$1.8 million Series Seed financing, \$19 million Series A financing, \$35 million Series B financing*, \$30 million Series C financing and \$15 million Series D financing
- Renovia's \$42 million Series B Financing from Perceptive Advisors, Ascension Ventures, Longwood Fund, Inova Strategic Investments, Cormorant Asset Management, OSF Ventures and Western Technology Investment
- Ichorion Therapeutics in its \$2.5 million Series Seed financing and sale to Cerecor
- BlueSphere Bio in its \$10 million Series A financing
- Jounce Therapeutics' \$56 million Series B financing*
- Abingworth Life Sciences' venture investment in Avedro*
- Buoy Health in its \$15 million Series B financing
- 406 Ventures investment in Iora Health's \$28 million Series C financing*
- Vensun Pharmaceuticals' \$22.5 million Series C financing from Deerfield Capital, Perceptive Advisors and JW Asset Management*
- Carevive Systems' \$7.2 million Series B financing from HLM Venture Partners and Long River Ventures*
- Clora in its \$3.3 million seed financing
- Elemental Machines' Series Seed financing*
- Apprentice FS in its \$8 million Series A financing
- Dental Torch in its \$10 million financing with Bessemer Venture Partners
- OCV Partners in their investment in the \$53 million Series C financing for Finch Therapeutics

M&A Transactions

- Therachon in its sale to Pfizer valued up to \$810 million
- Agilis Biotherapeutics in its \$200 million sale to PTC Therapeutics
- QPID Health in its sale to eviCore healthcare*
- Taris Biomedical in its sale of its Liris program to Allergan *
- Predictive Bioscience in its sale of its anatomic pathology business unit to Miraca Life Sciences*
- Scientia Advisors in its sale to Precision Health*

Prior to joining Cooley, Ryan was a partner at Goodwin Procter.

*handled prior to joining Cooley

Education

Boston University School of Law
JD, 2007

Westfield State College
BA, 2004

Admissions & Credentials

Massachusetts